Abstract
Paediatric keratoconus is often an undiagnosed condition that results in many cases being untreated. As this patient population has a vulnerable developing visual system, a delay in treatment can lead to lifelong visual consequences. Published studies demonstrate that keratoconus progresses at a faster rate in children compared to adults and that CXL can arrest disease progression also in paediatric patients. Current barrier to the CXL treatment may be partly due to the lack of compliance during a procedure performed using local anaesthesia. In addition, children may not comply with instructions to avoid eye rubbing that increases the risk of regression over time and the chance for postoperative infection.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call